The diagnostic approach to CD relies primarily on the detection of tissue transglutaminase IgA antibodies (tTG-IgA); in subjects with IgA deficiency, IgG against tTG, endomysial (EMA), or deamidated gliadin peptides (DGP) could be considered [135]. This evidence concerns the gene TGM2 and selective IgA deficiency disease.